Genentech Seeks Trim Of Eli Lilly's Patent Invalidation Suit
Genentech Inc. on Wednesday urged a California federal judge to trim a suit seeking to invalidate its patents for a blood cancer treatment, saying Eli Lilly and Co. had failed to...To view the full article, register now.
Already a subscriber? Click here to view full article